Table I.

Completed phase iii trials studying neoadjuvant androgen deprivation therapy

Reference	Pts (n)	Risk group	rt (Gy)	Hormonal therapy (ht)	Median follow-up (years)	Scheme (ht months)	Timing of ht			Local failure	Biochemical ned	Overall survival
							Pre-rt (months)	rt (months)	Post-rt (months)
Pilepich et al., 200139, Roach et al., 200840 (rtog 86-10)	456	High (bulky disease)	65–70	tab	13.2	rt alone					20	34
					11.9	rt + ht (4)	2	2			35	42
										(10 years, p=0.18a)	(10 years, p=0.0001)	(10 years, p=0.12)
Laverdiere et al., 200441 (Quebec L-101)	161	Intermediate (∼70%)	64	tab	5	rt alone				nr	42	nr
						rt + ht (3)	3				66
						rt + ht (10)	3	2	5		69
											(7 years, p<0.05b)
D’Amico et al., 200442, D’Amico et al., 200843	206	Intermediate (79%)	70	tab	7.6	rt alone				nr	55	61
						rt + ht (6)	2	2	2		79	74
											(5 years, p<0.05)	(8 years, p=0.01)
Denham et al., 200544 (trog 96-01)	802	High (84%)	66	tab	5.9	rt alone				28	38	nr
						rt + ht (3)	2	5		17	52
		Intermediate (16%)				rt + ht (6)	2	2		12	56
										(5 years, p<0.05b)	(5 years, p<0.05b)
McGowan et al., 200938 (rtog 94-08)	1979	Low (35%)	66	tab	9.2	rt alone				39	59	57
					9.1	rt + ht (4)	2	2		21	74	62
		Intermediate (54%)								(2 yearsc, p=0.001)	(10 years, p=0.01)	(10 years, p=0.03)
		High (11%)

^aNo failure rates given.

^bNo statistically significant difference between the hormonal therapy arms.

^cPositive re-biopsies at 2 years.

Pts = patients; rt = radiation therapy; ned = no evidence of disease; tab = total androgen blockade; nr = not reported.